Explore 3 Stock Ideas & Industry Insights Download Free Report

Sorrento Therape

Company price
0.0003 USD 0.00(0%)
Last update at 2026-11-13T14:30:00Z
VOLUME
69284
Market Cap
0.22M

Momentum Score

…

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
-
Low
0.02
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sorrento Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, cell therapies and non-opioid pain treatments; its long-term growth may be driven by clinical trial readouts, regulatory approvals and licensing or partnership opportunities. Investors may find it attractive for a diversified pipeline and platform capabilities that could support commercialization if development programs succeed.

Major risks are high clinical and regulatory failure probability, ongoing need for external financing with dilution risk, and operational or governance uncertainty from prior restructurings.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
64.27M
Revenue Per Share
0.13
Gross Profit TTM
-157.47M
Debt / Equity
-6.21
ROE
-378.92%
Net Debt
110.87M
ROCE
-263.59%
Diluted EPS TTM
-0.07

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -561.75M -462.53M -310.58M -359.58M -213.78M
Minority interest -4.91M -0.81M -15.95M -70.94M -8.99M
Net income -559.33M -429.01M -308.57M -359.10M -203.54M
Selling general administrative 182.34M 196.86M 116.18M 103.56M 63.64M
Gross profit 29.39M 39.87M 30.05M 19.20M 14.13M
Reconciled depreciation 13.24M 12.46M 11.01M 10.99M 9.05M
Ebit -382.00M -399.77M -206.58M -198.14M -152.18M
Ebitda -364.52M -383.45M -191.87M -183.10M -143.13M
Depreciation and amortization 17.48M 16.32M 14.71M 15.04M 9.05M
Non operating income net other -67.28M -22.98M -51.73M -67.75M -10.60M
Operating income -378.50M -368.05M -201.53M -195.18M -150.43M
Other operating expenses 441.34M 420.95M 241.51M 226.61M 150.67M
Interest expense 8.57M 10.22M 20.18M 36.14M 57.63M
Tax provision -2.42M -33.52M -2.01M -0.47M -6.27M
Interest income - - 0.02M 1.09M 0.92M
Net interest income -8.57M -10.22M -20.16M -35.05M -56.71M
Non recurring 188.94M - - - -
Income tax expense -2.42M -33.52M -2.01M -0.47M -6.27M
Total revenue 62.84M 52.90M 39.99M 31.43M 21.19M
Total operating expenses 407.89M 407.92M 231.57M 214.38M 143.61M
Cost of revenue 33.45M 13.03M 9.94M 12.24M 7.06M
Total other income expense net -183.25M -94.48M -109.05M -164.39M -63.36M
Net income from continuing ops -559.33M -429.01M -308.57M -359.10M -207.51M
Net income applicable to common shares -572.84M -428.32M -298.46M -292.07M -203.54M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 472.84M 694.82M 535.82M 557.63M 624.09M
Intangible assets 136.90M 259.70M 73.67M 63.31M 66.28M
Other current assets 3.14M 7.48M 3.72M 27.19M 16.17M
Total liab 494.51M 616.69M 395.09M 524.88M 416.59M
Total stockholder equity -21.67M 78.13M 140.73M 32.76M 207.50M
Deferred long term liab 0.89M 38.13M 42.32M 44.04M 15.56M
Other current liab 249.59M 67.41M 40.45M 44.35M 34.95M
Common stock 0.05M 0.03M 0.03M 0.02M 0.01M
Capital stock 0.05M 0.03M 0.03M 0.02M 0.01M
Retained earnings -1959.45M -1386.60M -958.28M -659.82M -367.75M
Other liab - 283.18M 156.05M 158.47M 131.83M
Good will 80.27M 79.53M 43.55M 38.30M 38.30M
Other assets - 1216.65M 300.50M 49.92M 50.57M
Cash 23.63M 36.66M 56.46M 22.52M 158.74M
Total current liabilities 327.92M 139.45M 96.48M 115.21M 61.62M
Current deferred revenue 0.65M 1.11M 4.49M 3.64M 2.70M
Net debt 110.87M 200.91M 112.93M 268.26M 74.55M
Short term debt 30.17M 43.52M 26.83M 39.58M 10.15M
Short long term debt 16.29M 31.98M 23.21M 36.26M 10.15M
Short long term debt total 134.50M 237.58M 169.39M 290.78M 233.29M
Other stockholder equity 1939.29M 1464.29M 1122.88M 738.66M 577.19M
Property plant equipment 51.97M 41.33M 31.86M 29.89M 24.38M
Total current assets 96.37M 172.99M 86.23M 67.59M 179.56M
Long term investments 17.18M 51.27M 256.40M 25.23M 27.98M
Net tangible assets -235.78M -260.48M 47.92M -23.02M 104.89M
Short term investments 26.34M 90.22M 256.40M - 0.30M
Net receivables 24.47M 18.71M 15.51M 14.51M 4.36M
Long term debt 19.13M 110.63M 92.26M 199.09M 223.14M
Inventory 9.98M 8.11M 1.83M 3.36M 2.90M
Accounts payable 47.52M 27.41M 24.71M 27.63M 13.82M
Noncontrolling interest in consolidated entity -3.06M -0.62M -24.42M -45.83M -1.97M
Accumulated other comprehensive income 1.50M 1.03M 0.52M -0.27M 0.01M
Common stock total equity 0.05M 0.03M 0.03M 0.02M 0.01M
Retained earnings total equity -1959.45M -1386.60M -958.28M -659.82M -367.75M
Treasury stock -49.46M -49.46M -49.46M -49.46M -49.46M
Non currrent assets other -37.97M -73.25M -60.88M -10.43M 50.57M
Non current assets total 376.47M 521.83M 449.59M 490.04M 444.52M
Capital lease obligations 99.09M 94.97M 53.93M 55.43M -
Long term debt total 19.13M 110.63M 92.26M 199.09M 223.14M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -28.52M 124.77M -39.92M -38.17M -21.20M
Change to liabilities 16.41M 16.76M 0.08M 19.96M 15.46M
Total cashflows from investing activities -28.52M 79.85M -39.92M -38.17M -21.20M
Net borrowings -92.24M -35.91M -186.98M 25.41M 173.38M
Total cash from financing activities 311.72M 181.33M 174.24M 78.89M 326.00M
Change to operating activities - 5.07M 8.89M 8.59M 7.31M
Net income -577.76M -429.14M -314.41M -363.01M -212.53M
Change in cash -13.03M -19.80M -24.30M -132.56M 192.90M
Begin period cash flow 36.66M 56.46M 80.77M 213.33M 20.43M
End period cash flow 23.63M 36.66M 56.46M 80.77M 213.33M
Total cash from operating activities -293.86M -281.82M -159.54M -173.00M -111.77M
Issuance of capital stock 402.33M 201.82M 317.87M 47.70M 83.61M
Depreciation 13.24M 12.46M 11.01M 10.99M 9.05M
Other cashflows from investing activities -14.86M 34.54M -33.40M -26.73M -10.00M
Change to inventory -9.51M 8.62M 10.20M - -
Change to account receivables -5.68M -2.96M -1.05M -10.62M -1.62M
Sale purchase of stock 403.53M 217.25M -55.00M 56.55M 61.35M
Other cashflows from financing activities 97.69M 65.16M 116.94M 34.26M 288.12M
Change to netincome 284.29M 118.97M 136.37M 151.01M 65.40M
Capital expenditures 13.66M 8.87M 37.58M 11.44M 11.20M
Change receivables -5.68M -2.96M -1.05M -10.62M -1.62M
Cash flows other operating -14.85M 11.29M 8.47M 18.68M 11.92M
Cash and cash equivalents changes -10.66M -20.64M -25.22M -132.28M 193.04M
Change in working capital 69.55M -2.79M 3.80M 7.25M 6.00M
Stock based compensation 74.85M 90.19M 31.42M 12.65M 6.21M
Other non cash items 128.09M 83.39M 110.77M 159.50M 85.62M
Free cash flow -307.51M -290.69M -197.12M -184.44M -122.96M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SRNE
Sorrento Therape
-
-%
0.00 - 1.18 0.00 4.01 2.06 -0.25
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Sorrento Therape

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

4955 Directors Place, San Diego, CA, United States, 92121

858 203 4100

949

Name Title Year Born
Dr. Henry H. Ji Ph.D. Chairman, President & CEO 1964
Dr. Scott Schaus Ph.D. Chief Technology Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…